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ABSTRACT 
Idiopathic myelofibrosis is a rare chronic myeloproliferative
disease leading to extramedullary hematopoiesis (myeloid
metaplasia) with splenomegaly. The liver and less frequently
other organs including the lung can be involved, therefore
portal hypertension is relatively common. Pulmonary hyper-
tension (PH) is only occasionally reported, although recent
studies have suggested an association between PH and
myeloproliferative disorders. 
We present a case of PH diagnosis by echocardiography in a
patient affected by idiopathic myelofibrosis with portal
hypertension. 
Keywords: Echocardiography, idiopathic myelofibrosis, portal
hypertension, pulmonary hypertension.
RIASSUNTO 
La mielofibrosi idiopatica è una rara forma di malattia mielo-
proliferativa che porta ad una ematopoiesi extramidollare
(metaplasia mieloide) con splenomegalia. Possono essere
coinvolti più organi, compreso il polmone, ma il bersaglio d’e-
lezione è il fegato ed un’ipertensione portale risulta perciò re-
lativamente frequente. Un’ipertensione polmonare è stata in-
vece segnalata solo occasionalmente, nonostante alcune re-
centi segnalazioni suggeriscano una connessione tra malattie
mieloproliferative ed ipertensione polmonare.
Viene qui riportato un caso di ipertensione polmonare dia-
gnosticata con ecocardiografia in un paziente affetto da mie-
lofibrosi idiopatica con ipertensione portale.
Parole chiave: Ecocardiografia, ipertensione polmonare, iper-
tensione portale, mielofibrosi idiopatica.  
INTRODUCTION
‘Idiopathic myelofibrosis’ (IM), ‘agnogenic myeloid
metaplasia’ or ‘myelofibrosis with myeloid metapla-
sia’ are synonymous for a rare chronic myeloprolif-
erative disease. Although the exact molecular and
pathogenic mechanisms are not defined, a clonal
defect in bone marrow stem cells leads to
extramedullary hematopoiesis (myeloid metaplasia)
with splenomegaly. This phenomenon can involve
the liver, and less frequently other organs including
the lung [1,2]. Considering the course of the dis-
ease, portal hypertension (POH) is relatively com-
mon. Pulmonary hypertension (PH) is only occa-
sionally reported [3-5], although recent studies
have suggested an association between PH and
myeloproliferative disorders [6]. Major prognostic
indices at the current time are advanced age, 
anemia, hypercatabolic symptoms, leukocytosis or
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0 leukopenia, circulating blast cells, and cytogenetic
abnormalities considered at risk for leukemic trans-
formation [6].
We present a case of PH diagnosis by echocardio -
graphy in a patient affected by IM with POH; poss -
ible pathogenic links are then debated on the basis
of a brief review of the literature. 
CASE REPORT 
A 71 year-old woman was admitted to our hospital
because of exertional dyspnea that had become
progressive over the past month, atypical chest
pain, mild peripheral edemas, and palpitations.
There was no history of heart and/or lung disease,
with the exception of two previous episodes of
acute pneumonia, respectively two years and one
year ago. Fifteen years earlier, diagnosis of IM had
been made by means of a bone marrow biopsy; the
patient then underwent hematological treatment in
day hospital regime at our Institute; her current ther-
apy was oncocarbide and allopurinol. 
On admission, body temperature was 36.7°C;
blood pressure was 120/90 mm Hg, heart rate was
96/min, rhythmic; breathing rate was 24/min. A
mild systolic murmur was audible on the right
parasternal margin. Respiratory sounds were sub-
stantially normal. Inferior edge of the liver was pal-
pable about 3 cm below the costal arch and the
spleen reached the umbilicus. No ascites was
detected. Slight peripheral edemas were present. 
Hematological data included a white blood cell
count of 12.8 x 103/ml; hemoglobin was 7.2 g/dl.
AST and ALP transaminases were elevated. Platelets
were 268 x 103/ml. C3 and C4 were normal. Lupus
anticoagulant, antinuclear and anticardiolipin anti-
bodies were negative. The assay for fibrinogen
degradation products (FDP) was slightly positive
(275 U, normal range up to 250 U). PT, PTT and fib-
rinogen values were within normal range.
Spirometry showed a slight restrictive pattern
(FEV1/FVC 105%, TLC 83% of predicted) with nor-
mal DLCO (performed after repeated transfusions of
blood, to reach a hemoglobin concentration of
about 11 g/dl). Arterial blood gas analysis showed pH
7.46, pO2 was 56 mm Hg, pCO2 was 29.7 mm Hg;
SaO2 was 91.0%, and bicarbonate concentration
was 21.4 mmol/L. 
ECG showed normal sinus rhythm and incomplete
right bundle branch block. Pattern S1, Q3, T3 was
not present. Echocardiography showed enlarged
right cardiac chambers, while left chambers were
normal: a severe tricuspid valve insufficiency was
detected and estimated pulmonary artery systolic
pressure was 85 mm Hg. Pulsed wave Doppler and
Tissue-Doppler Imaging at the mitral valve annulus
level did not show other than first-degree left ven-
tricular diastolic dysfunction, compatible with the
age of the patient. Pulmonary function tests
revealed a slight deficit with restrictive pattern (total
lung capacity 80% of predicted maximum) without
significant reduction in DLCO. Chest X-ray and com-
puterized tomography (CT) before and after contrast
showed enlarged cardiac silhouette but normal
lung parenchyma. Lung scan resulted consistent
with a very low probability of pulmonary thrombo -
embolism. Color-Doppler abdomen ultrasonogra-
phy confirmed homogeneous liver enlargement,
splenomegaly, and clear signs of POH. Color-flow
Doppler of leg veins was normal. Right heart
catheterization was not performed for technical 
reasons.
Immediate transfusions of red blood cells were
administered, and therapy by oxygen, furosemide,
spironolactone and warfarin was started, obtaining
mild improvement of symptoms. Two weeks later
the patient was discharged with a prescription of
furosemide, nifedipine (systemic blood pressure
was increased) and warfarin. Bosentan was ruled
out because of high levels of liver transaminases. A
check up 20 days later with Doppler ECG estimated
pulmonary artery systolic pressure to be 70 mm Hg.
We lost the patient at follow up; we know that she
died three months later from sepsis.
DISCUSSION
Dyspnea is a frequent symptom of IM, but it is usu-
ally related to abdominal discomfort or anemia.
When it depends on like-pneumonia foci of inter -
stitial pulmonary hematopoiesis, PH is not neces-
sarily detected [7]. Even hypoxia is not always relat-
ed to PH; a case of fatal respiratory failure during
IM has been reported, but pulmonary artery pres-
sure levels were not reported [8]. Our patient on
admission referred two previous episodes of pneu-
monia, but radiological documentation was not
available. However, X-ray, high-resolution CT, and
lung scan during recovery resulted negative for lung
involvement. Other symptoms of PH, e.g. exertional
dyspnea, palpitations, chest pain, syncope and
peripheral edema, are equally non specific and
diagnosis is often delayed [9]. Notably all of these
symptoms, with the exception of syncope, were
reported by our patient. Moreover PH has an impor-
tant prognostic relevance: Dingli et al. [10] reported
a median survival of 18 months after the diagnosis.
In this setting, echocardiography is a precious tool
to detect non invasively PH, although a hypermeta-
bolic state must be considered in some cases with
high cardiac output and elevated pulmonary artery
pressure without an increased pulmonary artery
resistance - to be evaluated by right heart catheter -
ization [10]. Although to date PH has been reported
only in a few cases of IM, a link is confirmed by the
greater incidence of PH and more advanced age of
onset with respect to the general population [11].
Pathogenic mechanisms of this association remain
speculative. 
Thrombocytosis, hypercoagulable states and 
erythroblastosis have been advocated in the genesis
of PH during IM [4,9,11]; a pro-thrombotic status in
IM is suggested by hematological and clinical
events (portal vein thrombosis, deep vein thrombo-
sis, amaurosis fugax, digital arterial thrombosis).
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normal, and in the absence of evident thrombosis
other mechanisms seem to be excluded by data
regarding coagulation; moreover both CT and lung
scan were not consistent with the suspicion of pul-
monary thromboembolism, raised by a slight posi-
tivity of assay for FDP. Without pulmonary angio -
graphy, however, microthrombosis of pulmonary
circulation cannot be excluded absolutely.
Auto-immunity is relevant for PH during systemic
connective tissue diseases (i.e. systemic lupus ery-
thematosus) [12], but also during liver cirrhosis
[13], and it has been documented in IM [14].
However, in this patient all indices of auto-immuni-
ty resulted negative.
In fact, a significant proportion of cases of IM are
affected by POH. In chronic liver diseases (i.e. liver
cirrhosis) PH may be associated with POH [15], i.e.
porto-pulmonary syndrome. Gut-derived toxins,
bypassing hepatic detoxification, could determine
pulmonary arterial vasoconstriction. Although rare
cases exist of PH and liver cirrhosis without POH
[16], some undetectable degree of porto-systemic
shunt cannot be excluded, and justifies also those
cases of IM without detection of portal hypertension
reported in the literature; furthermore an early
splenectomy, frequently performed in IM with
POH, could hypothetically prevent PH. The fact
however remains of cases of PH occurring in IM
after splenectomy. 
Changing perspective, Popat et al. [17,18] identi-
fied myelofibrosis as a complication of presenting
PH, primary or secondary. In idiopathic pulmonary
arterial hypertension clonal proliferation of
endothelial cells can occur: the articles debate the
possibility of a possible correlation with blood stem
cells, but data propend for a non clonal prolifera-
tion and a reactive process, differentiating this “sec-
ondary” myelofibrosis from IM. Although in our
patient diagnosis of IM had been made by bone
marrow biopsy, the observations of Popat et al. are
of absolute interest, raising new doubts and a new
possible hypothesis; however it seems mandatory to
search for myelofibrosis in patients affected by PH
(the association seems significant) and to verify
what the type of myelofibrosis is (idiopathic or sec-
ondary?).
CONCLUSION
In conclusion, an association seems to exist
between PH and IM, but the nature of this link
remains unclear. A correlation with POH, hypothe-
sized in the past, is fascinating but not completely
clarified, and not always detectable; new mecha-
nisms are continuously being proposed and further
data are needed to establish the exact relationship
between PH and IM. Moreover a significant inci-
dence of “secondary”, reactive myelofibrosis has
been reported in PH. In all cases patients with PH
show a severe prognosis, and Doppler echocardio-
graphy should be performed at the initial stage to
achieve an early diagnosis.
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FIGURA 1: CHEST X-RAY OF THE PATIENT IN SUPINE
POSITION
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